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Introduction 
The Ovarian Hyperstimulation Syndrome (OHSS) was first described in 1943 by Rydberg et al. as a loss of control over 
the intended therapeutic stimulation of the ovaries. In 1951, the first fatal case of OHSS was reported and it immediately 
became a potential complication associated with assisted reproductive techniques (ART), particularly with controlled 
ovarian stimulation (COS). Nowadays, it is considered the major risk related to ART just behind multiple pregnancies (1).  
In 2012, OHSS was reported in 0.6% European women undergoing a cycle of ovarian stimulation.  
The central factor in triggering OHSS is an hCG exposure, either endogenous or exogenous, and it is because of the 
different source of this hormone that becomes its principal classification (Table 1): 
• Iatrogenic OHSS or associated with COS 
• Sporadic OHSS or spontaneous in pregnancy 
Supraphysiological 
expression 
Excessive vascular 
permeability 
hCG 
LH/hCGR 
Granulosa and endothelial cells  
↑↑  VEGF mRNA 
 ↑↑  VEGFR-2 mRNA 
↑↑ VEGF 
↑↑ VEGFR-2  
Hypovolemia 
Protein-rich fluid to 
mesothelium superficies 
Ascites 
Oligúria 
Electrolytic imbalance 
Hypovolemic shock 
Haemoconcentration Thrombosis 
In both cases, it consists in a self-limiting syndrome in which the symptoms decline 10-14 days after its debut. The first symptoms are abdominal discomfort and distention, nausea, 
vomit and/or diarrhoea. At that point, vascular permeability increases resulting in protein-rich fluid from the intravascular space to mesothelium superficies, being this characteristic 
the cardinal feature of OHSS. The symptoms which follow this event depend on the severity of the syndrome (Figure 1)(2).  
Even though the main mediators of 
the syndrome are known, today many 
aspects of OHSS aetiology remain 
unclear. It has not been elucidated 
why only a group of patients develop 
this life-threatening syndrome.  
Figure 1. OHSS physiopathology and symptomatology (2)  
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Table 1. OHSS classification 
Type Iatrogenic OHSS Sporadic OHSS 
hCG source Exogenous Endogenous 
Debut 
~3-7 days post-hCG 
administration in COS 
~8-14th 
pregnancy week 
Incidence 
Mild: 20-33% COS 
Moderate: 3-6% COS 
Severe: 0’1-2% COS 
Indeterminable 
(literature based 
on case reports)  
Relevant results in BASIC RESEARCH 
Table 2. FSHR allelic variants and their functional consequences Adapted from OMIM (#608115, *136435)   
Authors 
Mutation 
(SNP) 
Location in FSHR 
Functional consequence of  mutated FSHR 
Constitutive 
activity 
FSH 
response 
hCG response TSH response 
Vasseur et al. 
(2003) 
T449I 
rs28928870 
Exon 10, helix III 
TMB domain 
No Yes Yes No 
Smits et al. 
(2003) 
D567N 
rs28928871 
Exon 10, helix VI 
TMB domain 
Yes Yes Yes Yes 
Montanelli et al. 
(2004) 
T449A 
rs121909663 
Exon 10, helix III 
TMB domain 
Yes Yes Yes. Yes 
De Leeener et al. 
(2006) 
I545T 
rs121909664 
Exon 10, helix V 
TMB domain 
Yes Yes Yes Yes 
De Leener et al. 
(2008) 
S128Y 
rs121909665 
Exon 5 LRRs in 
ectodomain  
No Yes Yes No 
TMB: transmembrane, SNP: single nucleotide polymorphism. Although allelic variants are mainly in transmembrane domain, because of receptor’s 
functional dichotomy between recognition and activation activities, ligand specificity is finally affected.  
Actual CLINICAL RESEARCH approach 
Current 
research of 
OHSS 
Basic research: 
• Syndrome aetiology 
Clinical research: 
• Prevention/Treatment strategies 
• Risk factors analysis  
• Short/long-term consequences 
analysis 
Aims and methodology 
The aims of this review are :  
 To show the most relevant results of OHSS basic research. Issues 
related to individual susceptibility and genetic aetiology. 
 To show the focus of OHSS recent clinical research.   
Scientific literature has been searched on PubMed database prioritizing 
those reviews and meta-analysis published in the last 5-10 years using 
keywords such as ‘OHSS’ ([AND]) ‘pathology’, ‘VEGF’, ‘genetics’, 
‘treatment’, ‘cancer’ etc.   
Genetic aetiology of OHSS 
The multiple reported cases of sporadic OHSS in members of the same family sparked the interest in the research of a possible genetic aetiology of the 
syndrome. In 2003, Vasseur et al. and Smits et al. confirmed this hypothesis by detecting activating polymorphisms in FSHR gene. Over the years, 
many investigators have identified other polymorphisms sequencing the same gene and, in all cases, it has been demonstrated that FSHR mutations 
broaden the specificity of this receptor (Table 2).  Then, it can be activated either by FSH or hCG. In some cases it can also be activated by TSH as a 
consequence of the homology between all these hormones (Figure 3)(4,5).  
FSHR mutations and sporadic OHSS 
INDIVIDUAL SUSCEPTIBILITY 
The failure in establishing OHSS aetiology during the last decade has contributed to focus the actual 
research on the clinical side of the syndrome. The aims of the most recent papers are towards the 
revision of drugs for the prevention and treatment, and the analysis of long-term consequences.  
During pregnancy hCG reaches a maximum 
concentration about 8-10 weeks, which can 
cross-activate mutated FSHR (Figure 3) 
Active FSHR stimulates massive follicular 
recruitment and enlargement.  
Granulosa cells of these follicles acquire 
LH/hCG receptors and finally develop into 
corpus luteum.  
hCG promotes VEGF and VEGFR-2 
supraphysiological synthesis and secretion in 
corpus luteum.  
Vascular permeability increases excessively 
beginning the development of sporadic OHSS.  
Clinical approach: Even though FSHR mutations provided, for the first time, an 
explanation about the aetiology of spontaneous OHSS, as there are sporadic 
cases in pregnant without any FSHR mutations the standardized screening 
of allelic variants in all pregnant women is not currently considered.  
Individual susceptibility in high-risk patients 
High-risk OHSS patient’s determination previous to ovarian stimulation has been the most useful tool in the prevention of the syndrome at the clinical practice . 
 
 
Nevertheless, the long-standing problem has been that, in some cases: 
 Patients considered at high-risk for OHSS have not developed the syndrome 
 Patients not considered at high-risk for OHSS have developed the syndrome 
Recent studies have concluded that the responsible for this intricacy are the soluble VEGF receptors (sVEGFR) (Figure 2).  
Those receptors bind to VEGF and avoid its function by preventing the interaction with its receptor VEGFR-2 (3).  
Thus, the vascular permeability remains stable. 
 
 
 
sVEGFR analysis for OHSS prevention 
sVEGFR use in OHSS treatment 
High-risk patients Who develop OHSS 
Who don’t develop OHSS 
↓sVEGFR and ↑VEGF 
↑sVEGFR and ↓VEGF 
Dopamine agonists for OHSS prevention/treatment 
Dopamine agonists such as Cabergoline (Cb2) have been in use since 2002 for OHSS prevention and 
treatment (Figure 4). Recent published meta-analysis conclude that (7):  
Cb2 reduces OHSS incidence among high-risk patients who undergo a COS protocol. 
Results are better if it is used for the prevention than for the treatment.  
Cb2 has no adverse effect on pregnancy as the fertilization and implantation remain unaltered.  
VEGF physiological function is preserved 
 
Although the results, evidences obtained about the 
benefits of dopamine agonists are still unreliable. Meta-
analysis have been judged to be at high risk of selection 
and information bias, reducing the overall quality.  
Nevertheless, the principal limitation of these drugs is 
that they are only useful for iatrogenic OHSS cases. 
Clinical research LIMITATION:  
All results coming from OHSS clinical research are considered unavoidably of low quality as a 
consequence of the lack of a standardised definition of high-risk patients, lack of an uniform 
classification of OHSS severity, lack of standardised protocols used, etc.  
 
Figure 4. Dopamine action on VEGF/VEFGR-2 pathway. 
Active Dp-r2 inhibits VEGFR by blocking its intracellular 
phosphorylation and promoting its internalization.  
Figure  3. Mutated FSHR can be activated by endogenous hCG triggering sporadic OHSS at the 
8th pregnancy week (4).  
OHSS and ovarian cancer 
A recent study published in 2013 suggested the possible connection between OHSS and a higher risk 
of ovarian cancer. This speculation was a result of studies which established a relationship between: 
Oestrogen and ovarian cancer 
Ovarian stimulation and ovarian cancer 
Figure 5. Ascitic fluid with a cytological diagnostic of 
malignancy. Atypical cells with dark cytoplasm, rough-
grained nucleus and multiple nucleoli. (Ly:leukocytes; 
Meso:mesothelialcells;Hi:histiocytes;PMN:polymorphonuclear)
(B and C 200X)) 
Hypothesis: There is a causative relationship between 
iatrogenic OHSS and ovarian cancer.  
Study: Cytology of ascitic fluid cells recovered from 
patients with severe OHSS and long-term follow-up. 
Results: Cytological results suggested ovarian malignancy 
in most patients (Figure 5), but none developed malignant 
ovarian tumour during the study period.  
No relationship between OHSS and  ovarian cancer  
Unreliable results owing to selection bias and ↓n 
CONCLUSIONS 
Summarizing the results and discussions of this literature review it can be concluded that: 
• Currently OHSS is considered one of the highest risks associated with ART and is described as an 
idiopathic syndrome because the aetiology has not been completely elucidated.  
• Actual research can be divided in a basic and a clinical side, each one with different aims.  
• Among high-risk patients there is an individual susceptibility determined by sVEGFR.  
• There are genetic cases of OHSS in pregnancy due to FSHR mutations, which broaden its specificity. 
The detection of carrier pregnant is not contemplated by physicians.   
• In sporadic OHSS the allelic variant Asn680 is useful as a severity predictor.  
• It has been suggested that dopamine agonists reduce OHSS incidence without affecting pregnancy 
rate and that there is no causative association between OHSS and ovarian cancer.  
• It is necessary to standardise the definition, classification and treatment protocols in clinical 
research.  
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What about 
iatrogenic 
OHSS? 
Nowadays, FSHR polymorphisms have not been related to iatrogenic OHSS. Accordingly, the preventive screening of these allelic 
variants in all women before undergoing COS is not also considered.  
In 2000, Al-Hendy defined FSHR gene polymorphisms at two specific sites, Thr307Ala and Ser680Asn, which reduced FSHR protein 
responsiveness to exogenous FSH and, as a result, the effectiveness of ovarian stimulation treatment and the likelihood of developing 
OHSS. Many studies have evaluated the relationship between Ser680Asn and OHSS development (6): 
Ser680Asn polymorphism is not specific enough to predict the syndrome.  
Asn680 is useful to prognosticate the syndrome among OHSS patients  Essential to focus the treatment.  
Risk factors                    Young women (30-35y), low IMC, PCOS, ↑ antral follicles nº, ↑ oestradiol... 
Figure 2.  Normal (Group1) and high-risk 
women who don’t develop (Group2) and who 
develop OHSS (Group3). sVEGFR1 plasma 
concentration is significantly lower in group3.  
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